Should you sell Procter & Gamble Company or reduce the position?
Calculate what you would remove, what you would retain, and which assumptions support continuing to own it.
Price as of Oct 17, 2026, 10:45 PM UTC (polygon last daily bar) · Evidence through Oct 13, 2026
What has changed in the case for owning it?
Market Ontology's model values Procter & Gamble Company at $103.08 per share against $159.35 (-35.3%). 8 dated developments in the last 45 days reach the position.
| Development | Evidence | Assumption affected | Consequence for the case |
|---|---|---|---|
| Oct 13, 2026 · Walmart and Procter & Gamble Advance Over 1.3% Against Broad Market Softness | 2 sources | margin compression headwind against stable top-line pricing | Mixed |
| Sep 22, 2026 · Procter & Gamble Faces $1.4B FY27 Earnings Drag as Q4 Sales Volumes Flatline | 2 sources | input-cost pass-through limitation to margins | Weakens the case for owning |
| Sep 22, 2026 · Procter & Gamble Flags $1.4B FY27 Earnings Headwind as Q4 Volume Growth Stalls | 1 source | operating margin compression on slowing consumer pass-through | Weakens the case for owning |
| Sep 22, 2026 · Procter & Gamble Faces $1.4B After-Tax Earnings Headwind in FY27 | 1 source | input cost inflation and price elasticity capping volume growth | Weakens the case for owning |
| Sep 22, 2026 · Procter & Gamble Flags $1.4B Profit Drag in FY27 as Q4 Volume Stalls | 2 sources | operating margin compression from input costs and stagnant volume | Weakens the case for owning |
What changes if you sell?
| Keep current position | Sell selected quantity | Exit position | |
|---|---|---|---|
| Shares remaining | 100 | 50 | 0 |
| Estimated proceeds after included transaction costs | — | $7,964 | $15,927 |
| Downside case ($66.81) outcome | −$9,254 | −$4,627 | $0 |
| Upside case ($167.70) outcome | $835 | $418 | $0 |
| Remaining exposure | $15,935 | $7,968 | $0 |
Included costs: an assumed 5 bps for commission and spread. Tax treatment: not calculated; cost basis is not used in this comparison.
Undecided: sale proceeds and remaining exposure are calculated; replacement performance is left unresolved.
What would justify keeping the remaining position?
- Revenue growth (yr 1) holds near -7.91%: Trailing 4-year revenue CAGR of -7.9%, faded toward terminal growth over 5 years.
- Operating margin (steady-state) holds near 24.09%: Anchored to mean operating margin of 24.1% across the last 4 reported periods.
- Discount rate (WACC) holds near 6.1%: CAPM baseline: 5.10% risk-free + β-0.04 × 5.5% ERP = 4.85%.
What would justify investigating it again after an exit?
- Implied revenue growth (next yr → terminal) moves relative to 10.63%: Growth rate that reconciles the current share price to a 5y DCF holding margin, WACC and terminal g fixed.
- Implied steady-state FCF margin moves relative to 25.93%: FCF margin the market needs to justify the current price at modeled growth and WACC.
- The price falls below the downside value of $66.81.
Preserve the reasoning behind the sale.
Save the reduction you're considering, the evidence behind it, and your conditions for reviewing the remaining position. If you exit, keep the research and specify what would justify revisiting PG.
Should I buy?Should I hold?Should I hedge?How to hedgeImpact ledger